Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma

This study has been completed.
inVentiv Health Clinical
Information provided by (Responsible Party):
Prism Pharma Co., Ltd. Identifier:
First received: December 12, 2012
Last updated: October 20, 2015
Last verified: October 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: October 2015
  Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)